AMFR (autocrine motility factor receptor)

2011-08-01   Yalcin Erzurumlu , Petek Ballar 

Ege University, Faculty of Pharmacy, Biochemistry Department, Bornova, 35100, Izmir, Turkey

Identity

HGNC
LOCATION
16q12.2
IMAGE
Atlas Image
LEGEND
AMFR gene genomic location at chromosome 16q12.2 (minus strand).
LOCUSID
ALIAS
GP78,RNF45
FUSION GENES

DNA/RNA

Atlas Image
A. The alignment of AMFR mRNA to its genomic sequence. B. AMFR mRNA and its amino acid coding.

Description

The AMFR gene spans 64081 bases on minus strand. The DNA of AMFR consists of 14 exons and the coding sequence starts in the first exon.

Transcription

The AMFR gene has two transcripts. One of these transcripts is 2249 bp long and is a processed transcript with no protein product. 3598 bp long second AMFR transcript is a protein coding transcript (accession number: NM_001144). The DNA has been cloned in 1999 (Shimizu et al., 1999).

Proteins

Atlas Image
A schematic representation of the domain structure.

Description

AMFR belongs to the family of RING-Finger ubiquitin ligases. The complete protein contains 643 amino acids. The calculated molecular weight of AMFR is 73,0 kDa.
AMFR was originally isolated as a membrane glycoprotein from murine melanoma cells and was implicated in cell migration (Nabi and Raz, 1987). Subsequently, gp78/AMFR was identified as the tumor autocrine motility factor receptor mediating tumor invasion and metastasis (Nabi et al., 1990). A monoclonal antibody named 3F3A was generated against this protein and first sequence reported for human gp78/AMFR was in 1991 using this antibody (Watanabe et al., 1991). However, the protein product was only 321 amino acids (Watanabe et al., 1991). A sequence giving 643 amino acids protein product was cloned in 1999 (Shimizu et al., 1999).
gp78/AMFR has five to seven transmembrane domains according to different softwares like SACS MEMSAT and SOSUI. The protein has a long cytoplasmic tail composed of around 350 amino acids (Shimizu et al., 1999). Besides conveying E3 activity the multifunctional cytoplasmic tail is responsible for interaction with polyubiquitin, ubiquitin conjugating enzyme, p97/VCP and Ufd1. The RING finger domain of gp78/AMFR residing between amino acids 341 and 383 is a RING-H2 type domain containing two His residues in positions 4 and 5 (Fang et al., 2001). The Cue domain of gp78/AMFR residing between amino acids 456 and 497 is responsible for polyubiquitin binding and has been identified by having homologous sequences of yeast protein Cue1p (Ponting, 2000). The p97/VCP-interacting motif of gp78/AMFR consists of C-terminal amino acid residues between 614-643 and it is sufficient to bind to p97/VCP protein (Ballar et al., 2006). gp78/AMFR binds to its ubiquitin conjugating enzyme via a region called UBE2G2 binding region (G2BR) and this region is resides between amino acids 579 and 600 (Chen et al., 2006). Additionally, gp78/AMFR interacts directly with Ufd1 through residues 383-497 (Cao et al., 2007) and with INSIGs through its transmembrane domains (Song et al., 2005).

Expression

gp78/AMFR is relatively ubiquitously expressed in normal human cells, especially highly in liver, heart and lung. Northern blot analysis detected a 3.5-kb AMFR transcript in mouse heart, brain, lung, liver, skeletal muscle, kidney, and testis, but not in spleen (Shimizu et al., 1999). gp78/AMFR is overexpressed in certain malignant tumors and human cancers of the lung, gastrointestinal tract, breast, liver, thymus, and skin (Chiu et al., 2008; Sjöblom et al., 2006; Tsai et al., 2007; Joshi et al., 2010).

Localisation

Endoplasmic reticulum membrane, multi-pass transmembrane protein (Fang et al., 2001).

Function

In 2001, it has been reported that gp78/AMFR possesses ubiquitin ligase (E3) activity (Fang et al., 2001) and can ubiquitinate both itself and other proteins for proteasomal degradation. gp78/AMFR is a member of multiprotein complex functioning in endoplasmic reticulum associated degradation (ERAD). gp78/AMFR not only functions as an E3 during ERAD but also couples retrotranslocation and deglycosylation to ubiquitination (Ballar et al., 2006; Li et al., 2005).

Homology

Homologues have been found in various species like bovine, chimpanzee (99.8 % homology), chicken, zebra fish, rat, C. elegans and mouse. gp78/AMFR shares 94.7 % of homology with murine gp78/AMFR.

Mutations

Somatic

D605V mutation has been reported in breast cancer (Sjöblom et al., 2006). Several SNPs have been found in gp78/AMFR gene both at coding regions and at UTRs and introns. See SNP database at NCBI.

Implicated in

Entity name
Sarcoma metastasis
Note
gp78/AMFR targets KAI1, a known metastasis suppressor protein for ubiquitin mediated proteasomal degradation (Tsai et al., 2007). Thus gp78/AMFR has role in metastasis of human sarcoma. Furthermore, a human sarcoma tissue microarray study documents that tumors with low gp78 expression has higher levels of KAI1 and high gp78 level lower KAI1 expression in tumors (Tsai et al., 2007).
Entity name
Breast cancer
Note
gp78/AMFR expression in gp78 transgenic mammary glands induces mammary gland hyperplasia, increases duct number and network density and shows down-regulation of KAI1 metastasis suppressor (Joshi et al., 2010). Additionally, gp78/AMFR has been identified as one of the most mutated genes in breast cancer (Sjöblom et al., 2006). Consistently, gp78/AMFR is overexpressed in human breast cancer and is negatively associated with patients clinical outcome (Jiang et al., 2006).
Entity name
Gastric carcinoma
Note
gp78/AMFR expression may be associated with the progression and invasion of gastric carcinoma as well as the prognoses of the patients (Hirono et al., 1996). Furthermore, by using same 3F3A antibody it was reported that gp78/AMFR expression is associated with lymph node metastasis and peritoneal dissemination in gastric carcinoma (Taniguchi et al., 1998).
Entity name
Colorectal cancer
Note
gp78/AMFR expression is correlated high incidence of recurrence of the patients with colorectal cancer (Nakamori et al., 1994).
Entity name
Melanoma
Note
It was showed by using 3F3A antibody that gp78/AMFR protein expression in human melanoma cell lines correlates to their metastatic potential. While in thin tumors weak/heterogenous gp78/AMFR expression predominated, in thick tumors the strong gp78/AMFR expression profile was predominant (Tímár et al., 2002).
Entity name
Lung cancer
Note
Using immunohistochemical staining the gp78/AMFR expression was showed to be associated with histologic type of tumor, mainly in adenocarcinoma (Kara et al., 2001).
Entity name
Hepatocellular carcinoma
Note
The expression of gp78/AMFR significantly increased in hepatocellular carcinoma compared with pericarcinomatous liver tissues. Furthermore, there is a strong correlation between AMFR expression and invasion and metastasis of HCC (Wang et al., 2007).
Entity name
Bladder carcinoma
Note
While in normal urothelium gp78/AMFR is not expressed, its expression is increased in bladder carcinoma specimens (Otto et al., 1994).
Entity name
Cardiovascular diseases and hypercholesterolemia
Note
Accumulation of sterols in ER membranes triggers the binding of HMG CoA reductase, the rate limiting enzyme of cholesterol biosynthesis, to the Insig1-gp78/AMFR complex which is essential for the ubiquitination and proteasomal degradation of HMGCoA-reductase (Goldstein et al., 2006; Jo and DeBose-Boyd, 2010). gp78/AMFR is also the E3 ligase of apolipoprotein B100, the protein component of atherogenic lipoproteins, overproduction of which is a common feature of human dyslipidemia (Liang et al., 2003).
Entity name
Cystic fibrosis
Note
gp78/AMFR degrades mutant cystic fibrosis transmembrane conductance regulator (CFTRΔF508) associated with cystic fibrosis (Ballar et al., 2010; Morito et al., 2008).
Entity name
Metabolism and disposition of drugs
Note
gp78/AMFR participates in proteasomal degradation of CYP3A4, a dominant human liver cytochrome P450 enzyme functioning in the metabolism and disposition of drugs and responsible for many adverse drug-drug interactions (Kim et al., 2010; Pabarcus et al., 2009).
Entity name
Chronic obstructive pulmonary disease
Note
gp78/AMFR expression is increased with the severity of emphysema (Min et al., 2011).
Entity name
Neurodegenerative diseases
Note
gp78/AMFR may play a protective role against mutant huntingtin toxicity. Mutant huntingtin hinders polyubiquitin binding to the cue domain of gp78/AMFR and causes aggregation of ligase (Yang et al., 2010). gp78/AMFR also enhances ubiquitination, degradation, suppression of aggregation of mutant SOD1 associated with amyotrophic lateral sclerosis (ALS), and mutant ataxin-3 associated with Machado-Joseph disease. Furthermore, in spinal cords of ALS mice, gp78/AMFR expression is significantly is up-regulated (Ying et al., 2009).
Entity name
Alpha-1-antitrypsin deficiency
Note
gp78/AMFR targets mutant ATZ (Z-variant alpha-1-antitrypsin) associated with alpha-1-antitrypsin deficiency for the proteasomal degradation and increases its solubility (Shen et al., 2006).

Bibliography

Pubmed IDLast YearTitleAuthors

Other Information

Locus ID:

NCBI: 267
MIM: 603243
HGNC: 463
Ensembl: ENSG00000159461

Variants:

dbSNP: 267
ClinVar: 267
TCGA: ENSG00000159461
COSMIC: AMFR

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000159461ENST00000290649Q9UKV5
ENSG00000159461ENST00000492830R4GNG2
ENSG00000159461ENST00000563664H3BQM3
ENSG00000159461ENST00000565445H3BSK3
ENSG00000159461ENST00000567738H3BRK9

Expression (GTEx)

0
50
100
150

Pathways

PathwaySourceExternal ID
Protein processing in endoplasmic reticulumKEGGko04141
Protein processing in endoplasmic reticulumKEGGhsa04141
Metabolism of proteinsREACTOMER-HSA-392499
Post-translational protein modificationREACTOMER-HSA-597592
Asparagine N-linked glycosylationREACTOMER-HSA-446203
N-glycan trimming in the ER and Calnexin/Calreticulin cycleREACTOMER-HSA-532668
Calnexin/calreticulin cycleREACTOMER-HSA-901042
ER Quality Control Compartment (ERQC)REACTOMER-HSA-901032

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
161683772005Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase.133
173101452007A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate.112
164071622006The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site.105
195604202009Allosteric activation of E2-RING finger-mediated ubiquitylation by a structurally defined specific E2-binding region of gp78.86
180378952007The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation.73
170433532006Sterol-regulated degradation of Insig-1 mediated by the membrane-bound ubiquitin ligase gp78.56
234272662013Regulation of mitophagy by the Gp78 E3 ubiquitin ligase.49
176811472007Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase.41
198644572010The E3 ubiquitin ligases Hrd1 and gp78 bind to and promote cholera toxin retro-translocation.41
239422352013Allosteric regulation of E2:E3 interactions promote a processive ubiquitination machine.40

Citation

Yalcin Erzurumlu ; Petek Ballar

AMFR (autocrine motility factor receptor)

Atlas Genet Cytogenet Oncol Haematol. 2011-08-01

Online version: http://atlasgeneticsoncology.org/gene/627/css/lib/dataTables.bootstrap.min.css